Silence ALS initiative will offer an integrated solution to identify, support and potentially treat nano-rare ALS patients. n-Lorem foundation and Columbia University receive a founding donation from Target ALS of $400,000 to formalize the Silence ALS initiative and...
Collaboration, with Support from the ADDF’s Diagnostics Accelerator, Will Create Funding Opportunities to Advance Potential Biomarkers in Related Neurodegenerative Diseases. The Alzheimer’s Drug Discovery Foundation (ADDF) and Target ALS announced today a new...
One of the early Target ALS-supported consortia studying C9orf72 ALS put forward the idea that it may be possible to treat ALS by targeting C9orf72 peptides directly. To move this idea forward, Target ALS connected Neurimmune, a biotechnology company with a group of...
The ALS drug KPT-350 was one of the first of a dozen therapeutic options to emerge from the Target ALS Innovation Ecosystem and is now poised for clinical trial thanks to the power of collaboration. Shortly after its launch, Target ALS forged and funded one of the...
